Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues

Overview

Journal Cardiovasc Ther

Publisher Hindawi

Date 2020 Apr 25

PMID 32328172

Citations 2

Authors

Monica Verdoia

Cyril Camaro

Elvin Kedhi

Marco Marcolongo

Harry Suryapranata

Giuseppe De Luca

Affiliations

Soon will be listed here.

Abstract

Conflicting results have been reported so far in pooled analyses and studies evaluating the optimum duration of dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) patients. However, randomized clinical trials dedicated to this specific setting of higher thrombotic risk patients have only recently been completed, pointing at the noninferiority of a shorter strategy as compared to the traditional 12-month DAPT, furthermore allowing to reduce the risk of major bleeding complications. Therefore, a reconsideration of current clinical practice and guidelines should be certainly be advocated in light of the most recent updates, especially among ACS patients treated with percutaneous coronary intervention (PCI) and modern drug-eluting stents (DES). Our aim was to provide a comprehensive review of the available evidence on the optimal DAPT duration in ACS patients.

Citing Articles

Predictors of gastrointestinal bleeding in patients with acute coronary syndrome and the optimal duration of dual antiplatelet therapy.

Wang Y, Wu Y, Wang J, Zhang H, Du L, Wang K J Res Med Sci. 2024; 29:15.

PMID: 38808215 PMC: 11132419. DOI: 10.4103/jrms.jrms_452_22.

Coronary Physiology: Modern Concepts for the Guidance of Percutaneous Coronary Interventions and Medical Therapy.

Verdoia M, Rognoni A J Clin Med. 2023; 12(6).

PMID: 36983275 PMC: 10057250. DOI: 10.3390/jcm12062274.

References

Nakamura M, Iijima R, Ako J, Shinke T, Okada H, Ito Y . Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation. JACC Cardiovasc Interv. 2017; 10(12):1189-1198. DOI: 10.1016/j.jcin.2017.04.019. View

Verdoia M, Khedi E, Ceccon C, Suryapranata H, De Luca G . Duration of dual antiplatelet therapy and outcome in patients with acute coronary syndrome undergoing percutaneous revascularization: A meta-analysis of 11 randomized trials. Int J Cardiol. 2018; 264:30-38. DOI: 10.1016/j.ijcard.2018.02.095. View

Costa F, Vranckx P, Leonardi S, Moscarella E, Ando G, Calabro P . Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment.... Eur Heart J. 2015; 36(20):1242-51. DOI: 10.1093/eurheartj/ehv038. View

Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits P . Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. J Am Coll Cardiol. 2015; 65(23):2496-507. DOI: 10.1016/j.jacc.2015.04.017. View

Colombo A, Chieffo A, Frasheri A, Garbo R, Masotti-Centol M, Salvatella N . Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol. 2014; 64(20):2086-97. DOI: 10.1016/j.jacc.2014.09.008. View

Habib A, Finn A . Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration. Pharmacol Res. 2014; 93:22-7. PMC: 4369425. DOI: 10.1016/j.phrs.2014.12.003. View

Mauri L, Kereiakes D, Yeh R, Driscoll-Shempp P, Cutlip D, Steg P . Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014; 371(23):2155-66. PMC: 4481318. DOI: 10.1056/NEJMoa1409312. View

Yeh R, Secemsky E, Kereiakes D, Normand S, Gershlick A, Cohen D . Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016; 315(16):1735-49. PMC: 5408574. DOI: 10.1001/jama.2016.3775. View

Brener S, Mehran R, Dangas G, Ohman E, Witzenbichler B, Zhang Y . Relation of Baseline Hemoglobin Levels and Adverse Events in Patients With Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage strategY and Harmonizing Outcomes with RevasculariZatiON and Stents in Acute.... Am J Cardiol. 2017; 119(11):1710-1716. DOI: 10.1016/j.amjcard.2017.02.052. View

10.

Kim B, Hong M, Shin D, Nam C, Kim J, Ko Y . A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012; 60(15):1340-8. DOI: 10.1016/j.jacc.2012.06.043. View

11.

Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Kadota K, Yamaji K . Late adverse events after implantation of sirolimus-eluting stent and bare-metal stent: long-term (5-7 years) follow-up of the Coronary Revascularization Demonstrating Outcome study-Kyoto registry Cohort-2. Circ Cardiovasc Interv. 2014; 7(2):168-79. DOI: 10.1161/CIRCINTERVENTIONS.113.000987. View

12.

Choi S, Kim M, Cho Y, Park J, Lee K, Park T . Performance of PRECISE-DAPT Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy. Circ Cardiovasc Interv. 2018; 11(12):e006837. DOI: 10.1161/CIRCINTERVENTIONS.118.006837. View

13.

De Luca G, Dirksen M, Spaulding C, Kelbaek H, Schalij M, Thuesen L . Time course, predictors and clinical implications of stent thrombosis following primary angioplasty. Insights from the DESERT cooperation. Thromb Haemost. 2013; 110(4):826-33. DOI: 10.1160/TH13-02-0092. View

14.

Lee C, Ahn J, Park D, Kang S, Lee S, Kim Y . Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation. 2013; 129(3):304-12. DOI: 10.1161/CIRCULATIONAHA.113.003303. View

15.

Garot P, Morice M, Tresukosol D, Pocock S, Meredith I, Abizaid A . 2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents. J Am Coll Cardiol. 2016; 69(2):162-171. DOI: 10.1016/j.jacc.2016.10.009. View

16.

Mehran R, Baber U, Sharma S, Cohen D, Angiolillo D, Briguori C . Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019; 381(21):2032-2042. DOI: 10.1056/NEJMoa1908419. View

17.

Gilard M, Barragan P, Noryani A, Noor H, Majwal T, Hovasse T . 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol. 2014; 65(8):777-786. DOI: 10.1016/j.jacc.2014.11.008. View

18.

Wallentin L, Becker R, Budaj A, Cannon C, Emanuelsson H, Held C . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11):1045-57. DOI: 10.1056/NEJMoa0904327. View

19.

Yeh R, Kereiakes D, Steg P, Windecker S, Rinaldi M, Gershlick A . Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. J Am Coll Cardiol. 2015; 65(20):2211-21. PMC: 4678101. DOI: 10.1016/j.jacc.2015.03.003. View

20.

Kedhi E, Fabris E, van der Ent M, Buszman P, von Birgelen C, Roolvink V . Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ. 2018; 363:k3793. PMC: 6167608. DOI: 10.1136/bmj.k3793. View